Glenmark Pharmaceuticals Ltd share price logo

Glenmark Pharmaceuticals Ltd (GLENMARK)

₹1384.40.33%

bell
Get free price alerts. Set up your Free investment account to get Live Prices.

🔔 Stake Sale Alert

Glenmark Pharma to offload 7.84% stake in Glenmark Life Sciences via offer for sale

Overview
News
Financials
Q3 '23 Results
Technicals

Analyst Rating

based on 13 analysts

BUY

46.15%

Buy

38.46%

Hold

15.38%

Sell

Based on 13 analysts offering long term price targets for Glenmark Pharmaceuticals Ltd. An average target of ₹1177.92

Source: S&P Global Market Intelligence

Glenmark Pharmaceuticals Ltd Share analysis

Source: S&P Global Market Intelligence

Performance

  • Day's Low

    Day's High

    ₹1,350
    ₹1,397
  • 52 Week's Low

    52 Week's High

    ₹661
    ₹1,397
1 Month Return+ 15.88 %
3 Month Return+ 31.19 %
1 Year Return+ 105.76 %
Previous Close₹1,379.85
Open₹1,392.00
Volume26.48L
Upper Circuit-
Lower Circuit-
Market Cap₹38,937.73Cr

Key Statistics

P/E Ratio-25.93
PEG Ratio0.41
Market Cap₹38,937.73 Cr
P/B Ratio0.73
EPS32.78

Mutual Fund Holdings

Funds HoldingsPrev. 6M
HDFC Mid-Cap Opportunities Fund -Direct Plan - Growth OptionHDFC Mid-Cap Opportunities Fund -Direct Plan - Growth Option1.35%
Aditya Birla Sun Life Flexi Cap Fund Direct Plan GrowthAditya Birla Sun Life Flexi Cap Fund Direct Plan Growth1.12%
SBI Arbitrage Opportunities Fund Direct GrowthSBI Arbitrage Opportunities Fund Direct Growth0.47%
Aditya Birla Sun Life Mid Cap Fund Direct Plan GrowthAditya Birla Sun Life Mid Cap Fund Direct Plan Growth2.41%
HDFC Arbitrage Fund Wholesale Plan Growth Option Direct PlanHDFC Arbitrage Fund Wholesale Plan Growth Option Direct Plan0.92%

Company Information

Glenmark Pharmaceuticals Ltd is an Indian pharmaceuticals company listed on the National Stock Exchange and Bombay Stock Exchange. Established in 1977, the company manufactures and distributes branded and generic formulations, active pharmaceutical ingredients (API’s) and biosimilars. It has 18 manufacturing facilities in India, 7 in the U.S., 1 in Brazil and 1 in Mexico that span across the world catering to global requirements. Glenmark has taken several steps towards achieving a healthy presence in the global markets. In addition to its product portfolio, Glenmark’s aggressive acquisition strategy and product launch activities have helped expand its market reach. The company has been awarded numerous accolades over the years, including consecutive years of being ranked amongst the top 1000 world pharmaceutical companies. It continues to be a frontrunner in providing quality and affordable healthcare solutions in India and abroad.

Share Price: ₹1384.40 per share as on 11 Jul, 2024 04:01 PM
Market Capitalisation: ₹38,937.73Cr as of today
Revenue: ₹3,016.01Cr as on March 2024 (Q1 24)
Net Profit: ₹-1214.27Cr as on March 2024 (Q1 24)
Listing date: 10 Feb, 2000
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Pharmaceuticals Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Glenmark Pharmaceuticals Ltd

  • Glenmark Pharma to Sell Stake in Glenmark Life Sciences - 11 Jul, 2024

    Glenmark Pharmaceuticals has approved the sale of its remaining 7.84% stake in Glenmark Life Sciences via an offer for sale, worth around Rs 778 crore.

  • Glenmark Pharma to Sell Stake in Glenmark Life Sciences - 10 Jul, 2024

    Glenmark Pharmaceuticals has approved the sale of its remaining 7.84% stake in Glenmark Life Sciences via an offer for sale, valued at approximately Rs 778 crore.

  • Glenmark Pharmaceuticals Ltd Up 3.8% on NSE - 05 Jul, 2024

    Glenmark Pharmaceuticals Ltd rose for a third straight session, up 3.8% to Rs 1344.75 on the NSE. The stock has added around 11.15% in the last month and is up 101.23% YoY. The Nifty Pharma index, of which Glenmark is a constituent, has added around 6.43% in the last month.

  • Vitiligo Treatment Market to Grow at 10.81% CAGR by 2031 - 25 Jun, 2024

    The vitiligo treatment market is expected to grow from US$ 1529.97 million in 2024 to US$ 2832.16 million in 2031, with a CAGR of 10.81%. This growth can be attributed to various factors such as advancements in immunomodulatory therapies and increased funding for research.

  • Glenmark Pharmaceuticals Ltd Up for Fifth Straight Session - 19 Jun, 2024

    Glenmark Pharmaceuticals Ltd stock rose for the fifth consecutive session, up 0.7% to Rs 1251.5 on NSE. The company has added around 20.98% in the last month and is up 94.38% YoY. The PE of the stock is 24.61 based on TTM earnings ending March 24.

  • Glenmark Pharmaceuticals' Debt Reduced to Rs 9.91 Billion in March 2024 - 16 Jun, 2024

    Glenmark Pharmaceuticals' debt decreased from Rs 43.5 billion to Rs 9.91 billion in March 2024, with a net cash of Rs 6.69 billion. The company has more cash than debt and can manage its liabilities safely.

  • Glenmark Pharma Receives FDA Approval for Generic Medication; Analysts Maintain Buy Rating - 13 Jun, 2024

    Glenmark Pharmaceuticals has received approval from the US FDA to market a generic medication for stomach conditions. Meanwhile, KR Choksey has maintained a BUY rating on the stock with a target price of INR 1,403/share based on FY26E EPS.

  • Glenmark Pharma Receives FDA Approval for New Drug - 12 Jun, 2024

    Glenmark Pharmaceuticals has received final approval from the USFDA for its Esomeprazole Magnesium Delayed-Release Capsules. The drug is bioequivalent to Nexium 24 HR delayed-release capsules and achieved annual sales of approximately $259.2 million. Glenmark reported a net loss of ₹1,238.6 crore in Q4 FY24 with YoY revenue growth of 2%.

Insights on Glenmark Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, GLENMARK stock has moved up by 6.5%

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 8.59% to 10.55% in Mar 2024 quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 2.67K Cr → 3.86K Cr (in ₹), with an average increase of 30.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 139.1% return, outperforming this stock by 28.8%

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 23.71% to 21.38% in Mar 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 18.69% to 18.58% in Mar 2024 quarter

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 46.65% to 46.64% in Mar 2024 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, 149.93 Cr → -1.21K Cr (in ₹), with an average decrease of 243.4% per quarter

Company Financials

Value in ₹ crore
Q'1 24Q/Q Change
Revenue
₹3,016.01Cr
↑22.59%
Net Income
-₹1,214.27Cr
↑267.05%
Net Profit Margin
-40.26%
↑199.33%
2023Y/Y Change
Revenue
₹12,990.11Cr
↑5.57%
Net Income
₹377.40Cr
↓62.02%
Net Profit Margin
2.91%
↓63.99%
Value in ₹ crore
2023Y/Y Change
Total Assets
₹24,799.42Cr
↑7.22%
Total Liabilities
₹6,921.95Cr
↑8.32%
Value in ₹ crore
2023Y/Y Change
Operating Cash Flow
₹1,474.06Cr
↑21.22%

Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
46.64%
0.00
Foreign Institutions
21.38%
0.00
Mutual Funds
10.55%
0.00
Retail Investors
18.58%
0.00
Others
2.85%
0.00

Key Indicators

Glenmark Pharmaceuticals Ltd Valuation

Glenmark Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (-275.05x)

December 28, 2023

Today (-25.93x)

July 10, 2024

Industry (62.76x)

July 10, 2024

Highest (95.94x)

September 14, 2023

LowHigh

Earnings and Dividends

  • Glenmark Pharmaceuticals Ltd Earnings Results

    Glenmark Pharmaceuticals Ltd’s net profit fell -184.45% since last year same period to ₹-1218.28Cr in the Q4 2023-2024. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated -246.72% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Glenmark Pharmaceuticals Ltd Dividends May,2023

    In the quarter ending March 2023, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.36%.

    Read More about Dividends

Technicals Summary

Bearish

Neutral

Bullish

Bullish

Glenmark Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Glenmark Pharmaceuticals Ltd shares.

Glenmark Pharmaceuticals Ltd (GLENMARK) share price today is ₹1384.4

Glenmark Pharmaceuticals Ltd is listed on NSE

Glenmark Pharmaceuticals Ltd is listed on BSE

  • Today’s highest price of Glenmark Pharmaceuticals Ltd is ₹1397.
  • Today’s lowest price of Glenmark Pharmaceuticals Ltd is ₹1350.

PE Ratio of Glenmark Pharmaceuticals Ltd is -25.93

PE ratio = Glenmark Pharmaceuticals Ltd Market price per share / Glenmark Pharmaceuticals Ltd Earnings per share

Today’s traded volume of Glenmark Pharmaceuticals Ltd(GLENMARK) is 26.48L.

Today’s market capitalisation of Glenmark Pharmaceuticals Ltd(GLENMARK) is ₹38937.73Cr.

Glenmark Pharmaceuticals Ltd(GLENMARKPrice
52 Week High
₹1397
52 Week Low
₹661

Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1384.4. It is down -0.90% from its 52 Week High price of ₹1397

Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1384.4. It is up 109.44% from its 52 Week Low price of ₹661

Glenmark Pharmaceuticals Ltd(GLENMARKReturns
1 Day Returns
4.55%
1 Month Returns
15.88%
3 Month Returns
31.19%
1 Year Returns
105.76%